Novo will take an equity stake in Cellular Intelligence and is in line for future milestone payments and royalties. The startup plans to apply its AI platform to STEM-PD, a stem-cell-derived treatment Novo discontinued last October. Novo Nordisk has handed over STEM-PD, an experimental stem-cell therapy for Parkinson’s disease, to Cellular Intelligence, an AI biotech […]

This story continues at The Next Web